| [1] Tiseo M，Franciosi V，Grossi F，et al. Adjuvant chemotherapy for non-small cell lung cancer：ready for clinical practice?[J]. Eur J Cancer，2006，42 (1)：8-16. [2] Perez RP. Cellular and molecular determinants of cisplatin resistance[J]. Eur J Cancer，1998，34 (10)：1535-1542. [3] Baruah H，Barry CG，Bierbach U. Platinum-intercalator conjugates： from DNA-targeted cisplatin derivatives to adenine binding complexes as potential modulators of gene regulation[J]. Curr Top Med Chem，2004，4 (15)：1537-1549. [4] Hassa PO，Hottiger MO. The diverse biological roles of mammalian PARPS，a small but powerful family of poly-ADP-ribose polymerases[J]. Front Biosci，2008，13：3046-3082. [5] Hassa PO. The molecular“Jekyll and Hyde”duality of PARP1 in cell death and cell survival[J]. Front Biosci，2009，14：72-111. [6] Sun W，Zhang K，Zhang X，et al. Identification of differentially expressed genes in human lung squamous cell carcinoma using suppression subtractive hybridization[J]. Cancer Lett，2004， 212 (1)：83-93. [7] Ling B，Zheng H，Fu G，et al. Suppression of non-small cell lung cancer proliferation and tumorigenicity by DENND2D[J]. Lung Cancer，2013，79 (2)：104-110. [8] Yoshimura S，Gerondopoulos A，Linford A，et al. Family-wide characterization of the DENN domain Rab GDP-GTP exchange factors[J]. J Cell Biol，2010，191 (2)：367-381. [9] Lee ES，Son DS，Kim SH，et al. Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression[J]. Clin Cancer Res，2008，14 (22)：7397-7404. [10] Ziegler M，Oei SL. A cellular survival switch：poly (ADP-ribosyl) ation stimulates DNA repair and silences transcription [J]. Bioessays，2001，23 (6)：543-548. [11] Andriani F，Perego P，Carenini N，et al. Increased sensitivity to cisplatin in non-small cell lung cancer cell lines after FHIT gene transfer[J]. Neoplasia，2006，8 (1)：9-17. [12] Deng WG，Wu G，Ueda K，et al. Enhancement of antitumor activity of cisplatin in human lung cancer cells by tumor suppressor FUS1[J]. Cancer Gene Ther，2008，15 (1)：29-39. [13] Lai SL，Perng RP，Hwang J. p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells[J]. J Biomed Sci，2000，7 (1)：64-70. [14] Nakagawa T，Inoue Y，Kodama H，et al. Expression of copper- transporting P-type adenosine triphosphatase (ATP7B) correlates with cisplatin resistance in human non-small cell lung cancer xenografts[J]. Oncol Rep，2008，20 (2)：265-270. [15] Nishi M，Abe Y，Fujimori S，et al. The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo[J]. Oncol Rep，2005， 14 (2)：421-424. [16] Hassa PO，Haenni SS，Elser M，et al. Nuclear ADP-ribosylation reactions in mammalian cells：where are we today and where are we going?[J]. Microbiol Mol Biol Rev，2006，70 (3)：789-829. [17] Stordal B，Pavlakis N，Davey R. A systematic review of platinum and taxane resistance from bench to clinic：an inverse relationship[J]. Cancer Treat Rev，2007，33 (8)：688-703. |
